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Introduction
The reciprocal translocation between chromosomes 9 and
22 resulting in a shortened chromosome 22 (Philadelphia
chromosome) is the genetic hallmark of chronic myeloid
leukemia (CML). Consequently, the vast majority of patients
express a BCR-ABL1 mRNA fusion gene encoding a 210 kDa
tyrosine kinase (p210) which is constitutively activated and
hence the mainspring of leukemic transformation.1 With rare
exceptions, the p210 BCR-ABL1 is encoded by e13a2 and
e14a2 BCR-ABL1 transcripts, or in some cases by both of
them. 
One genomic breakpoint can result in variable transcript
types that differ in the number of involved BCR and (very
rarely) ABL exons due to alternative splicing.2 The p210 BCR-
ABL1 is associated with breakpoints located within the
“major” breakpoint cluster region (M-bcr) that comprises
exons 12-16, historically referred to as b1-b5. In these cases,
BCR exon 13 (e13) or BCR exon 14 (e14) is fused to ABL exon
2 (a2). Thereby the e14a2 fusion (3’ M-bcr breakpoint) as well
as the e13a2 fusion (5’ M-bcr breakpoint) can result in an
e13a2 mRNA since e14 is subjected to alternative splicing and
occasionally both transcripts occur together in multiplex PCR
as a product of the same clone.3 Both mRNA variants differ in
the presence or absence of the 75 base pairs of e14: the e13a2,
(lacking exon 14, also referred to as “b2a2”) and the e14a2
BCR-ABL1 transcript (“b3a2”).
Little is known about the functional relevance of the addi-
tional 25 amino acid residues of the e14a2 BCR-ABL1 onco-
protein. It has been hypothesized that spatial rearrangements
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The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding a 210
kDa tyrosine kinase which promotes leukemic transformation. A possible differential impact of the corresponding
BCR-ABL1 transcript variants e13a2 (“b2a2”) and e14a2 (“b3a2”) on disease phenotype and outcome is still a subject
of debate. A total of 1105 newly diagnosed imatinib-treated patients were analyzed according to transcript type at
diagnosis (e13a2, n=451; e14a2, n=496; e13a2+e14a2, n=158). No differences regarding age, sex, or Euro risk score
were observed. A significant difference was found between e13a2 and e14a2 when comparing white blood cells (88
vs. 65 x 109/L, respectively; P<0.001) and platelets (296 vs. 430 x 109/L, respectively; P<0.001) at diagnosis, indicating
a distinct disease phenotype. No significant difference was observed regarding other hematologic features, includ-
ing spleen size and hematologic adverse events, during imatinib-based therapies. Cumulative molecular response
was inferior in e13a2 patients (P=0.002 for major molecular response; P<0.001 for MR4). No difference was
observed with regard to cytogenetic response and overall survival. In conclusion, e13a2 and e14a2 chronic myeloid
leukemia seem to represent distinct biological entities. However, clinical outcome under imatinib treatment was
comparable and no risk prediction can be made according to e13a2 versus e14a2 BCR-ABL1 transcript type at diag-
nosis. (clinicaltrials.gov identifier:00055874) 
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ABSTRACT
of the adjacent domains might be a consequence and
altered cellular interactions might result in particular due
to the sequential arrangement of six hydrophobic residues
coded by exon e14.4 Interestingly, a novel lysine residue is
introduced at the e14a2 junction site due to codon disrup-
tion, which is not the case in the e13a2 fusion because the
resulting codon is identical with the non-rearranged a1a2
sequence. It has been assumed that this might contribute
to the immunogenicity of the e14a2 junction peptide. The
HLA-associated expression of this junction peptide as a 9-
mer on the surface of CML cells has been shown to pro-
voke a cytotoxic T-lymphocyte response.5
The clinical relevance of the additional 25 residues and
the specific fusion peptide of the e14a2 BCR-ABL1 onco-
protein were extensively studied in the pre-imatinib era.
However, the influence of the genomic breakpoint loca-
tion and the predominantly spliced mRNA variant on dis-
ease phenotype and outcome remained controversial.6
Regarding hematologic characteristics at diagnosis, the
observation of higher platelet counts in the e14a2 group
must now be considered in the light of reports to the con-
trary over the past two decades.4,7,8
There has still been no evaluation of distinct disease
characteristics and the prognostic implications of different
p210 BCR-ABL1 transcript types in a larger data set of
CML patients on imatinib treatment. In this study, we
analyze the long-term molecular, cytogenetic, and clinical
outcome of 1105 chronic-phase CML patients receiving an
imatinib-based treatment within the randomized German
CML Study IV.9
Methods
The randomized German CML Study IV compares four ima-
tinib-based treatment modalities in newly diagnosed chronic-
phase CML patients. Treatment arms comprise monotherapy
with imatinib 400 mg/d or 800 mg/d and combinations of imatinib
400 mg/d with interferon alpha (IFN-α) and low-dose cytarabine.9
IFN-α was administered at a dose of 1.5-3.0 x 106 IU three times
per week according to tolerability. Cytarabine was given in an
intermittent dose of 10 mg absolute up to 20 mg/m2 subcutaneous-
ly according to tolerability. The study was approved by the ethics
committees of the participating centers. Written informed consent
was obtained from all patients according to the Declaration of
Helsinki. The study is registered at clinicaltrials.gov identifi-
er:00055874 (http://clinicaltrials.gov). 
Definition of treatment response
Major cytogenetic response (MCyR), complete cytogenetic
response (CCyR), major molecular remission (MMR), accelerated
phase (AP), and blastic phase (BP) were defined according to
European LeukemiaNet (ELN) criteria.10,11 Deep molecular remis-
sion was defined as a 4-log reduction in BCR-ABL1 transcript lev-
els (MR4), i.e. a decline of BCR-ABL1 equal or below 0.01% com-
pared to the standardized baseline according to the International
Scale (IS).12 Disease progression was defined by the occurrence of
AP, BP, or death from any cause.
Multiplex-PCR, quantitative RT-PCR
The type of BCR-ABL1 transcript was determined via multiplex
RT-PCR from cDNA synthesized from total leukocyte RNA at
diagnosis.13 Expression of BCR-ABL1 and total ABL1 was deter-
mined by quantitative RT-PCR from cDNA and standardized
according to the IS as previously described.14,15 
Statistical analysis
Comparisons of base-line blood variables were made by the
Mann-Whitney-Wilcoxon test. Probabilities of overall survival
(OS) and progression-free survival (PFS) were calculated by the
Kaplan-Meier method and compared by log rank statistics. For
response parameters, cumulative incidences were calculated in
consideration of competing risks defined by AP, BC, and death.16
Comparisons between cumulative incidences were performed by
the Gray test. P=0.05 was considered significant. All calculations
were performed with SAS software v. 9.1.3 (SAS Institute, Cary,
NC, USA).
Results
Patients and transcripts
A total of 1311 patients were recruited until April 30,
2009. Ten patients had to be excluded from the study: no
CML (n=4), not in first chronic phase (n=4), withdrawal of
consent (n=2). Patients with primary IFN-α treatment
were switched to imatinib in case of failure and not sub-
jected to the transcript analysis (n=131). In 51 patients the
BCR-ABL1 transcript type was unknown. Atypical tran-
scripts were detected in 14 patients: e1a2 (n=3), e13a3
(n=1), e14a3 (n=4), e19a2 (n=6). The remaining 1105
patients with typical BCR-ABL1 transcripts were evalu-
able for response and survival analysis and presented at
diagnosis with e13a2 (n=451, 41%), e14a2 (n=496, 45%)
or both transcript types (n=158, 14%) (Online
Supplementary Table S1). According to protocol, patients
could be pre-treated with hydroxyurea or imatinib before
first clinical examination and differential blood count.
Therefore, 67 patients (hydroxyurea, n=48; imatinib,
n=19) were excluded from the analysis of base-line char-
acteristics (CONSORT diagram) (Online Supplementary
Figure S1).
A total of 105 patients were switched to second- or
third-line tyrosine kinase inhibitor (TKI) treatment at the
investigators’ discretion, usually due to intolerance or a
lack of response. The distribution of patients receiving
nilotinib (n=34), dasatinib (n=73) or bosutinib (n=3)
according to BCR-ABL transcript type is shown in the
Online Supplementary Table S2.
Disease characteristics at diagnosis
No correlation of transcript type with age or sex was
observed (Table 1). The analysis of initial blood counts
for both transcript groups revealed a significant differ-
ence in total leukocytes (WBC) and platelets. At diagno-
sis, e14a2 patients presented with a median WBC of 65 x
109/L compared to 88 x 109/L in the e13a2 group
(P<0.001) and 78 x 109/L in the e13a2+e14a2 group
(P=0.030) (Figure 1A) indicating a lower tumor load.
With regard to platelets, there was a significant differ-
ence that is inverse to the difference in WBC: 296 x 109/L
in the e13a2 group compared to 430 x 109/L in the e14a2
group and 420 x 109/L in the e13a2+e14a2 group
(P<0.001). (Figure 1B). No differences were observed in
hemoglobin concentration, differential counts of periph-
eral blood, or spleen size (Table 1). The different platelet
counts did not transform into a significant difference
between patients’ risk status according to Euro scores.
According to the absence of a systematic difference in
Euro score, age, and sex, the transcript groups were com-
pared without stratification for those covariates.
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Molecular response in total patient sample
Patients expressing one single transcript showed a dif-
ference in the cumulative incidence (CI) of MMR
(P=0.002), whereas the e13a2+e14a2 transcript group did
not differ to either side (not significant) (Figure 2). There
was a substantial difference in median time to MMR
when e13a2 was compared to e14a2 (18.4 vs. 14.2
months), while CI of MMR after five years of treatment
was 81% versus 85%.
Regarding the CI of MR4, the difference between e13a2
and e14a2 was also significant (P<0.001) (Figure 3) and even
more pronounced: median time to MR4 55.2 versus 32.4
months, while CI of MR4 after five years of treatment was
58% versus 76%. In terms of MR4, e13a2+e14a2 differed
from e14a2 (P=0.004) (Figure 3) but not from e13a2.
These findings suggest a better molecular response rate
in the e14a2 group as compared to e13a2, indicated by a
difference of approximately four months of median time
to MMR and 23 months to MR4. 
Molecular response in single treatment arms
If single treatment arms were analyzed with regard to
MMR, a significant difference in favor of e14a2 was only
seen for the imatinib 400 mg + IFN-α arm (n=331;
P=0.004) as compared to e13a2 (data not shown).
Concerning MR4, the imatinib 400 mg + IFN-α group
(n=331; P<0.001), the imatinib 400 mg + cytarabine group
(n=150; P=0.004) and the imatinib 800 mg group (n=324;
P=0.028) all showed significant differences if e14a2 and
e13a2 were compared.
Cytogenetic response
In contrast to molecular findings, no significant differ-
ence emerged when cumulative incidence of MCyR (data
not shown) and CCyR (Figure 4) were compared. The three
transcript groups varied between 6.8 and 7.8 months in
median time to MCyR, and between 10.1 and 11.4
months in median time to CCyR, therefore only slight dif-
ferences were observed.
Comparison of e13a2 versus e14a2 BCR-ABL1 in CML
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Figure 1. (A) Box plots of leukocyte counts (WBC) at diagnosis. E14a2 is associated with lower WBC (65 x 109/L, median) as compared to
e13a2 (88 x 109/L, P<0.001) and e13a2+e14a2 (78 x 109/L; P=0.030). (B) Box plots of platelet counts at diagnosis. E13a2 is associated with
lower platelet count (296 x 109/L, median) as compared to e14a2 (430 x 109/L; P<0.001) and e13a2+e14a2 (420 x 109/L; P<0.001). 
Figure 2. Cumulative incidence of major
molecular remissions (MMR). 
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Clinical outcome
No difference between the three transcript groups was
observed with regard to PFS and OS (Figures 5 and 6). 
Adverse events
Despite the disparities in blood counts at diagnosis, no
significant differences in the incidence of adverse hemato-
logic events (grade 3/4) under imatinib treatment were
observed.
BCR-ABL kinase domain mutations
In case of suspected resistance, a total of 690 mutation
analyses were performed in the study center, 108 of which
were positive. Twenty-seven different mutations could be
detected in 63 patients. The most common mutations
were T315I (n=13 patients), M244V (n=9), Y253H (n=7)
and E255K (n=7). No difference in the incidence of muta-
tions was observed in a comparison between BCR-ABL
transcript groups (Online Supplementary Table S3).
Discussion
The question as to whether or not the type of the indi-
vidually expressed BCR-ABL1 fusion transcript deter-
mines the phenotype of CML and might influence course
and prognosis had already been investigated extensively
in the pre-imatinib era. While distinct CML features could
be associated with the three major BCR-ABL1 types, p190,
p210, and p230,6 the biological significance of the two
p210 subtypes occurring in the vast majority of CML cases
remained controversial.17 Several studies could not find
any impact on clinical course or survival.18,19 Here we
report on the hematologic phenotype and outcome of
1105 imatinib-treated patients expressing one or both of
the different p210 BCR-ABL1 transcript types. 
Our data reveal a distinct phenotype of e13a2 and e14a2
CML, the latter of which is characterized by lower WBC
count (88 vs. 65 x 109/L) and higher platelet count (296 vs.
430 x 109/L), whereas there was no significant difference
in any of the other hematologic features, including spleen
size. A first report of a link between the e14a2 transcript
type and high platelet counts at diagnosis was provided in
199120 and questioned shortly after.21 Both papers reported
on small series of patients (n=57,20 n=4521). In a later analy-
sis of 119 patients, a higher platelet count was found only
in patients with WBC less than 100 x 109/L.22 In a cohort
of 88 patients, a significantly higher platelet count in
e14a2 patients was observed (306 vs. 616 x 109/L).4 A more
recent analysis of 202 cases could not find any hematolog-
ic differences at all.8 Our findings, derived from a large
cohort of patients, strongly support the former reports of
distinct blood counts for both transcript types, which
might reflect a specific disease biology. 
Assuming a distinct CML phenotype according to the
individual BCR-ABL1 transcript leads to the question as to
whether these phenotypes might be associated with spe-
cific patterns of TKI response. Regarding molecular
response, we found a clear advantage for the e14a2 group
of patients: median time to MMR was 14 versus 18
months, median time to MR4 was 32 versus 55 months
(Figures 2 and 3). This is in agreement with results of the
Italian GIMEMA working party that investigated 559
patients on imatinib treatment and found a significantly
shorter time to MMR in the e14a2 group.23 Vega-Ruiz et al.
analyzed 480 patients and found significantly lower BCR-
B. Hanfstein et al.
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Figure 3. Cumulative incidence of 4-log
molecular remissions (MR4). 
Table 1. Patients’ characteristics at diagnosis (median, range).
e13a2                 e14a2 e13a2+e14a2
Age (years) 52 (16-85)             53 (18-83) 50 (17-83) 
Sex (% female) 40.1                         40.5 32.9 
Hemoglobin (g/L) 122 (49-175)         125 (52-191) 122 (48-164) 
White blood cells 87.7                         65.3 78.0
(x 109/L) (3.0-571)               (2.8-630) (3.1-539) 
Platelets(x 109/L) 296.0                       430.0 419.5
(49-2582)              (34-3020) (127-1924) 
Blasts (%) 1 (0-21)                 1 (0-17) 1 (0-17) 
Basophils (%) 3 (0-26)                 4 (0-22) 3 (0-22) 
Eosinophils (%) 2 (0-9)                  2 (0-20) 2 (0-16) 
Monocytes (%) 2 (0-28)                 2 (0-19) 2 (0-20) 
Spleen size 1 (0-30)                 1 (0-30) 2 (0-30)
(cm below costal margin) 
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ABL1 levels in the e14a2 group at three, six, and nine
months.24 
In contrast, both studies found no difference in the
achievement of CCyR for e14a2 and e13a2 patients,
which is somewhat unexpected in the face of superior
molecular response in the e14a2 group. Likewise, our data
show no difference in the cumulative incidence of MCyR
and CCyR (Figure 4), which is in contrast to the molecular
findings. Distinct BCR-ABL1 transcript levels in the pres-
ence of identical proportions of leukemic bone marrow
cells given by cytogenetic response would imply a specific
transcription frequency of the particular BCR-ABL1 tran-
Comparison of e13a2 versus e14a2 BCR-ABL1 in CML
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Figure 4. Cumulative incidence of complete cytoge-
netic remissions (CCyR). 
Figure 5. Probability of progression-free survival
(PFS). 
Figure 6. Probability of overall survival (OS). 
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script type. To our knowledge, there are no data on this
question. Besides this explanation, a possible bias in PCR
amplification efficiency should also be examined. We per-
form quantitative RT-PCR on the LightCyclerTM 1.5 and
2.0 instruments (Roche Diagnostics, Mannheim,
Germany) using hybridization probes which allows the
use of relatively long PCR amplicons of 671 and 596 base
pairs for e14a2 and e13a2 transcripts. A similar PCR assay
is performed in many European laboratories. The effect of
the 75 base pair difference might be more significant in
PCR assays using shorter amplicons, e.g. using the
TaqManTM approach.25 An evaluation of disparate efficien-
cies affecting the comparability of molecular assessments
of patients with different transcript types is warranted.
Lucas et al. investigated 78 patients and showed a faster
achievement of CCyR in the e14a2 group, which was
explained by a higher kinase activity of e13a2 BCR-ABL1
reflected by pCRKL.26 Taking into account that in the
study of Lucas et al. CCyR was also given as CCyR equiv-
alence, i.e. BCR-ABL1 transcript levels less than 1%, this
result might also be affected by disparate PCR efficiencies. 
In contrast to the above findings, better response rates
for e13a2 have also been reported. A small series of
Brazilian patients (n=22) showed better molecular
response,27 while a cohort of Indian patients (n=87)
showed superior cytogenetic response.28 Another analysis
of Indian patients (n=202) showed no difference in molec-
ular and cytogenetic response rates.8
With regard to clinical end points such as failure-free,
transformation-free, progression-free, and overall survival,
none of the larger cohorts, including our own, showed a
significantly different outcome on imatinib treatment
according to the BCR-ABL1 transcript type (Figure 5 and
6).23,24,26 Despite conflicting data regarding molecular and
cytogenetic response in several studies, this might suggest
a general agreement that the type of BCR-ABL1 transcript
does not serve as a prognostic marker at diagnosis.
It has been reported that patients develop circulating T
cells that react with an HLA BCR-ABL1 junction peptide
complex on the surface of e14a2 BCR-ABL1 positive cells.5
A differential immunogenicity of e14a2 BCR-ABL1 cells
could be postulated that might lead to a distinct response
to treatment with IFN-α, which is known to stimulate T-
cell response. In the subgroup of CML Study IV treated
with a combination of IFN-α and imatinib (n=331), no dif-
ference in survival was observed according to transcript
type. However, a significant difference regarding MMR
and MR4 was still observed despite the lower number of
cases. No other treatment arm showed the same effect for
MMR. This might support the notion of a distinct immune
response to e14a2 BCR-ABL1 cells. On the genomic level,
the group of patients expressing both transcripts at diag-
nosis is identical to the e14a2 group and does not harbor
two distinct clones.2 However, in this group, exon e14 is
spliced to a significant extent resulting in two mRNA tran-
scripts. The group expressing both transcripts seems to be
similar to e13a2 with regard to base-line leukocyte count
(Figure 1A) and similar to e14a2 with regard to base-line
platelet count (Figure 1B). In terms of molecular response,
the group expressing both transcripts might resemble
e13a2, as suggested by CI of MR4 (Figure 3). This might
argue against an altered immune response conferred by
e14a2.
We conclude that the type of BCR-ABL1 transcript is
reflected by different leukocyte and platelet counts at
diagnosis, which might represent a distinct phenotype and
disease biology. In our data, superior molecular response
was observed in e14a2 patients. This is not paralleled by
cytogenetic response where no difference was observed
with regard to CCyR and MCyR. The differences in
molecular response do not translate into differences in sur-
vival. Therefore, the type of BCR-ABL1 transcript should
be taken into account when BCR-ABL1 levels are inter-
preted to assess imatinib response. However, the type of
transcript allows no risk stratification at diagnosis. 
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